Its efficacy has been evaluated in a randomized-controlled trial (TRIAL 1) involving 675 patients with unresectable or metastatic melanoma BRAF V600E mutation-positive receiving vemurafenib 960 mg twice a day (337) or dacarbazine (338). This evidence concerns the gene BRAF and metastatic melanoma.